Reported results
- Consolidated revenue was $54.5 million for the third quarter of 2026 (GAAP).
- Net loss was $14.7 million for the third quarter of 2026 (GAAP).
- Adjusted EBITDA was $3.1 million for the third quarter of 2026 (non-GAAP).
- DefenCath net revenue was $17.2 million for the third quarter of 2026 (GAAP).
- Basic and fully diluted earnings per share were $(0.19) for the third quarter of 2026 (GAAP).
Guidance
- Full-year 2026 consolidated revenue guidance of $325 to $345 million.
- Full-year 2026 adjusted EBITDA guidance of $130 to $140 million.
- Full-year 2026 cash-based OpEx guidance of $140 to $145 million.
- Anticipated revenue contribution of $125 million to $150 million for the full-year 2027 from the Heron transaction.
Notes
The Company suspended previously issued 2027 DefenCath revenue guidance in light of changes to the CMS reimbursement framework.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
